Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Paul Edward Sax, M.D.

Co-Author

This page shows the publications co-authored by Paul Sax and Elena Losina.
Connection Strength

1.322
  1. Projecting 10-year, 20-year, and Lifetime Risks of Cardiovascular Disease in Persons Living With Human Immunodeficiency Virus in the United States. Clin Infect Dis. 2017 10 15; 65(8):1266-1271.
    View in: PubMed
    Score: 0.183
  2. The clinical role and cost-effectiveness of long-acting antiretroviral therapy. Clin Infect Dis. 2015 Apr 01; 60(7):1102-10.
    View in: PubMed
    Score: 0.151
  3. HIV cure strategies: how good must they be to improve on current antiretroviral therapy? PLoS One. 2014; 9(11):e113031.
    View in: PubMed
    Score: 0.149
  4. Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. HIV Clin Trials. 2010 Sep-Oct; 11(5):248-59.
    View in: PubMed
    Score: 0.112
  5. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS. 2008 Oct 01; 22(15):2025-33.
    View in: PubMed
    Score: 0.098
  6. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005 Nov 01; 41(9):1316-23.
    View in: PubMed
    Score: 0.079
  7. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr. 2005 May 01; 39(1):69-77.
    View in: PubMed
    Score: 0.077
  8. Effectiveness of antiretroviral therapy after protease inhibitor failure: an analytic overview. Clin Infect Dis. 2004 Jun 01; 38(11):1613-22.
    View in: PubMed
    Score: 0.072
  9. Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States. J Acquir Immune Defic Syndr. 2020 02 01; 83(2):148-156.
    View in: PubMed
    Score: 0.054
  10. Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study. Clin Infect Dis. 2017 Jun 01; 64(11):1612-1614.
    View in: PubMed
    Score: 0.045
  11. Cost-effectiveness of genotype testing for primary resistance in Brazil. J Acquir Immune Defic Syndr. 2015 Feb 01; 68(2):152-61.
    View in: PubMed
    Score: 0.038
  12. Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. HIV Med. 2011 Feb; 12(2):97-108.
    View in: PubMed
    Score: 0.029
  13. Assessing the performance of a computer-based policy model of HIV and AIDS. PLoS One. 2010 Sep 09; 5(9).
    View in: PubMed
    Score: 0.028
  14. The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat. 2011 Jul; 18(7):506-12.
    View in: PubMed
    Score: 0.027
  15. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009 Mar 15; 48(6):806-15.
    View in: PubMed
    Score: 0.025
  16. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. HIV Med. 2007 Oct; 8(7):439-50.
    View in: PubMed
    Score: 0.023
  17. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis. 2007 Oct 15; 45(8):1062-70.
    View in: PubMed
    Score: 0.023
  18. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006 Nov; 44(11):990-7.
    View in: PubMed
    Score: 0.021
  19. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006 Jul 01; 194(1):11-9.
    View in: PubMed
    Score: 0.021
  20. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med. 2005 Mar; 118(3):292-300.
    View in: PubMed
    Score: 0.019
  21. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003 Dec 01; 115(8):632-41.
    View in: PubMed
    Score: 0.017
  22. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med. 2002 Nov 25; 162(21):2478-86.
    View in: PubMed
    Score: 0.016
  23. Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. J Acquir Immune Defic Syndr. 2002 Sep 01; 31(1):27-37.
    View in: PubMed
    Score: 0.016
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.